

**Arent Fox**

ATTORNEYS AT LAW

Richard J. Berman

Patent Attorney

Phone 202/857-6232

Fax 202/638-4810

b rmanr@ar ntfox.com

www.arentfox.com

FACSIMILE TRANSMITTAL COVER SHEET**Date:** October 18, 2000**No. of Pages:** 6
(Including Cover Sheet)**PLEASE DELIVER TO:****Name:****Fax Number:****Verify Number:**

Examiner Marianne DiBrino, Ph.D. (703) 305-7401

(703) 308-0061

Attorney Number: 1552 **Client/Matter Number:** 100564-9014**Hard Copy Sent:** No

Comments: Per our discussion, attached is a copy of the Preliminary Amendment we filed on September 28, 1999 in the above-referenced application.

Richard J. Berman

THIS FACSIMILE CONTAINS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S) NAMED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT OF THIS FACSIMILE, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL FACSIMILE TO US AT THE ADDRESS BELOW VIA THE POSTAL SERVICE. THANK YOU

Please Call As Soon As Possible If Transmission Is Not Complete: 202/857-6119**Arent Fox Kintner Plotkin & Kahn, PLLC**

1050 Connecticut Ave., N.W., Washington, D.C. 20036-5339

#6
46
11/23/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

ENDL, et al.

Serial Number: Cont. of 08/967,242
- filed November 5, 1997

Filed: June 30, 1999

For: ANTIGEN-SPECIFIC ACTIVATED T LYMPHOCYTES, DETECTION AND USE

PRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

September 28, 1999

Sir:

Please amend the above-identified application as follows:

IN THE CLAIMS:Please *cancel* claims 1-24, 28-30, 35, 36 and 41-45 without prejudice or disclaimerand *add* the following new claims:

Sub 46
46. A peptide derived from glutamic acid decarboxylase having a length of
at most 25 amino acids and comprising

(a) a peptide of at least 6 amino acids of an amino acid sequence selected
from the group consisting of SEQ ID NOS: 2, 3 and 19-39, or

(b) a peptide or peptide derivative having a length of 6 to 25 amino acids
which exhibits a specificity or/and affinity which is essentially equivalent to that of the
peptide (a) and includes anchor positions for binding to alleles of MHC class II
molecules DR3 or DR4.